Live Feeds
● LIVE Updated 12d ago · 21 sources tracked

Kidney healing improves after protein blockade, with less scarring and faster recovery

A drug created at UCLA to treat heart damage after heart attacks may also repair injured kidneys. Lab research indicates the drug helps kidney tissue regenerate. This treatment targets the ENPP1 protein to lower scarring and speed up recovery.

RSS Source map (17)

What changed

New lab research confirms the drug's potential to repair injured kidneys.

Live updates

  1. UCLA Heart Drug Shows Potential for Kidney Repair

    A drug created at UCLA to treat heart damage after heart attacks may also repair injured kidneys. Lab research indicates the drug helps kidney tissue regenerate. This treatment targets the ENPP1 protein to lower scarring and speed up recovery.

    What's confirmed:

    • A drug developed at UCLA for heart tissue repair after heart attacks may also help kidney tissue repair and regenerate.
    • The drug targets the ENPP1 protein to reduce scarring and accelerate recovery.
    confidence 100%

  2. UCLA Heart Repair Drug Shows Potential for Kidney Regeneration

    Researchers found that a drug developed at UCLA for heart tissue repair after heart attacks may also help kidney tissue repair and regenerate. The drug targets the ENPP1 protein to reduce scarring and accelerate recovery.

    What's confirmed:

    • A drug developed at UCLA for heart tissue repair after heart attacks may also help kidney tissue repair and regenerate.

    Still unconfirmed:

    • The drug AD-NP1 blocks the ENPP1 protein to reduce scarring and speed up recovery in mice.
    confidence 90%

  3. UCLA Drug AD-NP1 Accelerates Kidney Repair and Reduces Scarring

    Researchers at UCLA developed a drug called AD-NP1 that blocks the ENPP1 protein to help kidney tissue regenerate. The drug was originally designed for heart tissue repair after heart attacks. It has shown the ability to reduce scarring and speed up recovery in mice.

    What's confirmed:

    • The drug AD-NP1 blocks the ENPP1 protein to accelerate kidney repair and reduce scarring in mice.
    • AD-NP1 was originally developed at UCLA to assist heart tissue repair after a heart attack.
    • The drug is currently in FDA-approved Phase 1 trials.

    Still unconfirmed:

    • Mayo Clinic researchers found a new way kidneys regulate water balance that could treat polycystic kidney disease.
    • GLP-1 receptor agonists may influence inflammatory processes in skin diseases.
    • Over 850 million people suffer from various stages of chronic kidney disease.
    confidence 90%